Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Good
|
New words:
Aegerion, Africa, argument, Australia, Caribbean, carrier, Columbia, contended, CRL, dextro, diarrhea, driver, eagle, East, EGFR, Epidermal, equating, EVOMELA, excellence, GK, head, hearing, Hope, Hyperion, Ira, irreversibly, lapatinib, Lastly, magnitude, meaningful, MM, moderate, neck, Nonclinical, noncurrent, NSCLC, overcharging, overturned, partnership, passion, pegfilgrastim, prejudice, preliminarily, prophylactic, propriety, receptor, redemption, repay, restraining, resubmitted, RRZ, SA, Sagent, Servier, signaling, Simplifying, SPI, Sucampo, Switzerland, trastuzumab, treaty, TURBT, unchanged, unlabeled, unsecured, Zealand
Removed:
abated, AmerisourceBergen, behave, Bexxar, building, buying, called, CareTM, circulate, combining, computing, cultural, deductible, deeper, deficient, desired, discipline, distance, diversified, divide, evolve, existed, faced, generated, GMP, Hamni, hire, hiring, HopeTM, hyperphosphatemia, inclusion, indemnification, inexperience, inherit, innermost, instability, Iodine, issuing, layer, liver, LLCTM, lucanthone, modifying, operational, outlook, peripheral, pivotal, political, prostate, publicationCancer, pursue, radiopharmaceutical, referenced, Regeneron, reinstatement, repaired, repatriation, retroactively, RITTM, RRZTM, sBLA, shipment, shortage, social, spreading, supplemental, Tositumomab, train, treating, underperforming, Vice
Filing tables
Filing exhibits
Related press release
SPPI similar filings
Filing view
External links
EXHIBIT 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-37585, 333-52331, 333-73009, 333-92855, 333-37180, 333-38710, 333-42852, 333-51388, 333-60966, 333-64432, 333-64444, 333-102587, 333-105814, 333-108658, 333-110103, 333-115759, 333-121612, 333-125208, 333-135029, 333-142628, 333-150260, 333-190413, 333-194823 and 333-208760 on Form S-3, and Registration Statement Nos. 333-30345, 333-54246, 333-106427, 333-119833, 333-134566, 333-160312, 333-160705, 333-164014, 333-176681, and 333-202761 on Form S-8 of our report dated March 12, 2014, with respect to the consolidated financial statements and schedule of Spectrum Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Spectrum Pharmaceuticals, Inc. for the year ended December 31, 2015.
/s/ Ernst & Young LLP
Irvine, California
March 14, 2016